
    
      Randomized, multi-center, double-masked, vehicle-controlled, Phase 1/2 study to evaluate the
      safety, tolerability, and efficacy of OTX-CSI in subjects with dry eye disease. The subjects
      will be followed for approximately 16 weeks after product insertion
    
  